41 research outputs found
L-dopa and dopamine-(R)-alpha-lipoic acid conjugates as multifunctional codrugs with antioxidant properties
A series of multifunctional codrugs (1-4), obtained by joining L-Dopa (LD) and dopamine (DA) with
(R)-R-lipoic acid (LA), was synthesized and evaluated as potential codrugs with antioxidant and iron-chelating
properties. These multifunctional molecules were synthesized to overcome the pro-oxidant effect associated
with LD therapy. The physicochemical properties, together with the chemical and enzymatic stabilities of
synthesized compounds, were evaluated in order to determine both their stability in aqueous medium and
their sensitivity in undergoing enzymatic cleavage by rat and human plasma to regenerate the original drugs.
The new compounds were tested for their radical scavenging activities, using a test involving the Fe (II)-
H2O2-induced degradation of deoxyribose, and to evaluate peripheral markers of oxidative stress such as
plasmatic activities of superoxide dismutase (SOD) and glutathione peroxidase (GPx) in the plasma.
Furthermore, we showed the central effects of compounds 1 and 2 on spontaneous locomotor activity of
rats in comparison with LD-treated animals. From the results obtained, compounds 1-4 appeared stable at
a pH of 1.3 and in 7.4 buffered solution; in 80% human plasma they were turned into DA and LD. Codrugs
1-4 possess good lipophilicity (log P > 2 for all tested compounds). Compounds 1 and 2 seem to protect
partially against the oxidative stress deriving from auto-oxidation and MAO-mediated metabolism of DA.
This evidence, together with the “in vivo” dopaminergic activity and a sustained release of the parent drug
in human plasma, allowed us to point out the potential advantages of using 1 and 2 rather than LD in
treating pathologies such as Parkinson’s disease, characterized by an evident decrease of DA concentration
in the brain
Codrugs linking L-Dopa and sulfur-containing antioxidants: new pharmacological tools against Parkinson’s Disease
A series of multifunctional codrugs (1-6) were synthesized to overcome the pro-oxidant effect associated with L-dopa (LD) therapy. Target compounds release LD and dopamine (DA) in human plasma after enzymatic hydrolysis, displaying an antioxidant effect superior to that of N-acetylcysteine (NAC). After intracerebroventricular injection of codrug 4, the levels of DA in the striatum were higher than those in LD-treated groups, indicating that this compound has a longer half-life in brain than LD
Novel chemotactic For-Met-Leu-Phe-OMe (fMLF-OMe) analogues based on Met residue replacement by 4-amino-proline scaffold: Synthesis and bioactivity
cis-(2S,4S) 4-Amino-proline (cAmp) and trans-(2S,4R) 4-amino-proline (tAmp) residues, bearing N-For or
N-Boc substituents at the two amino groups, have been incorporated into the potent chemotactic agent
fMLF-OMe in place of the N-terminal native (S)-methionine to give the analogues 17a–19a and 17b–19b.
The new ligands have been examined for their activity (chemotaxis, superoxide anion production and
lysozyme release) on human neutrophils as agonists and antagonists. Compounds 19a and 19b, bearing
two N-For groups at the proline scaffold, are active and selective chemoattractants. The ligand 18b, containing
N-For at the 4-amino group of the N-Boc-tAmp residue, exhibits significant chemotactic antagonism.
The influence of the different substitution at the N-terminal position of the new analogues is
discussed
Synthesis and biological evaluation of new active For-Met-Leu-Phe-OMe analogues containing para-substituted Phe residues. J.Pept.Sci, 18, 418-426, 2012.
In the present study, we report synthesis and biological evaluation of the N-Boc-protected tripeptides 4a-l and N-For protected tripeptides 5a-l as new For-Met-Leu-Phe-OMe (fMLF-OMe) analogues. All the new ligands are characterized by the C-terminal Phe residue variously substituted at position 4 of the aromatic ring. The agonism of 5a-l and the antagonism of 4a-l (chemotaxis, superoxide anion production, lysozyme release as well as receptor binding affinity) have been examined on human neutrophils. No synthesized compounds has higher activity than the standard fMLF-OMe tripeptide to stimulate chemotaxis, although compounds 5a and 5c with -CH(3) and -C(CH(3))(3), respectively, in position 4 on the aromatic ring, are better than the standard tripeptide to stimulate the production of superoxide anion, in higher concentration. Compounds 4f and 4i, containing -F and -I in position 4, respectively, on the aromatic ring of phenylalanine, exhibit significant chemotactic antagonism. The influence of the different substitution at the position 4 on the aromatic ring of phenylalanine is discussed
BICYCLIC PEPTIDES - SOLUTION CONFORMATION AND CA-2+ BINDING OF THE HETERODETIC BICYCLIC DECAPEPTIDE CYCLO(GLU1-LEU2-PRO3-GLY4-SER5-ILE6-PRO7-ALA8)-CYCLO(1-GAMMA- 5-BETA) PHE9-GLY10
The conformational behavior of a heterodetic bicyclic decapeptide (BCPLT) in the absence and in the presence of calcium ions has been studied by means of mono and two-dimensional nmr techniques. Free BCPLT possesses a quite compact structure stabilized by intramolecular bonds and turns. In the structure a cluster of carbonyls is located in a cavity that is supposed to be the cation binding site